Free Trial
→ Why More Investors Are Using Family Trusts to Protect Their Wealth (From SmartAsset) (Ad)tc pixel

Medicenna Therapeutics (TSE:MDNA) Stock Price Up 1% - Should You Buy?

Written by MarketBeat
September 20, 2025
Medicenna Therapeutics logo with Medical background

Key Points

  • Medicenna Therapeutics' stock price increased by 1% during trading, closing at C$1.00 after reaching a high of C$1.01.
  • The company's market capitalization stands at C$83.41 million, with a significant PE ratio of -6.25.
  • Medicenna is focused on developing immuno-oncology treatments, specifically targeting various cancers through its Empowered Cytokines and Superkines technology.
  • Five stocks to consider instead of Medicenna Therapeutics.

Medicenna Therapeutics Corp. (TSE:MDNA - Get Free Report)'s stock price rose 1% during trading on Friday . The stock traded as high as C$1.01 and last traded at C$1.00. Approximately 9,585 shares traded hands during trading, a decline of 78% from the average daily volume of 44,198 shares. The stock had previously closed at C$0.99.

Medicenna Therapeutics Price Performance

The company has a 50 day moving average price of C$0.99 and a 200 day moving average price of C$0.98. The firm has a market cap of C$83.41 million, a PE ratio of -6.25 and a beta of 2.80. The company has a current ratio of 11.40, a quick ratio of 4.65 and a debt-to-equity ratio of 0.88.

About Medicenna Therapeutics

(Get Free Report)

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Medicenna Therapeutics Right Now?

Before you consider Medicenna Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medicenna Therapeutics wasn't on the list.

While Medicenna Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.